Saxonov Serge 4

What Happened
Serge Saxonov, CEO of 10x Genomics (TXG), reported open-market sales totaling 28,893 shares for aggregate proceeds of about $709,057. The filings show two dispositions: 18,175 shares sold on 2026-05-22 at $24.44 each ($444,224) and 10,718 shares sold on 2026-05-26 at a weighted average price of $24.71 each ($264,833). These sales were reported as dispositions (S), not purchases.

Key Details

• Transaction dates and prices:
  • 2026-05-22: 18,175 shares @ $24.44 = $444,224
  • 2026-05-26: 10,718 shares @ weighted avg $24.71 = $264,833 (executed in multiple trades at prices from $24.45 to $24.88)
• Total sold: 28,893 shares for ~$709,057.
• Purpose: Shares were sold to cover tax withholding obligations related to restricted stock unit vesting (footnote F1).
• 10b5-1 plan: At least one transaction was effected under the reporting person's Rule 10b5-1 trading plan adopted Nov 29, 2025 (footnote F2).
• Trust holdings: Some shares are held in trusts (Andromeda Trust, Y/S Descendants' Trust, Y/S Pot Trust) for which Saxonov serves as trustee (footnotes F4–F6).
• Shares owned after the transaction: Not disclosed in the provided excerpt.
• Filing timeliness: Form 4 was filed 2026-05-27 for transactions dated 2026-05-22 and 2026-05-26; no late-filing flag is indicated in the provided data.

Context
These were sales (not purchases) and reported as routine transactions to satisfy tax-withholding on RSU vesting. Sales made under a pre-established 10b5-1 plan and tax-related dispositions are common and do not, by themselves, indicate the insider’s view of the company’s prospects.